

Application No.: 09/896,896  
Attorney Docket No: 0217us210  
Page 17 of 19  
-----

## REMARKS

### Amendments to the Specification

The paragraph at page 82 line 26 - page 83 line 3 (labeled "K." above) was amended in part to correct a typographical error in the N-terminal sequence of mature FHS-alpha, from "APD QDC" to "APDVQDC". Support for this amendment is found, for example, in amino acid positions 1-7 of SEQ ID NO:5 in the Sequence Listing as originally filed in the present application (e.g., page 101, 11<sup>th</sup> line from the bottom of the application as originally filed). This amendment introduces no new matter into the specification.

The remaining amendments to the specification are made to insert sequence identifiers ("SEQ ID NOs") into the specification as required by 37 C.F.R. § 1.821(d). These amendments introduce no new matter.

### Status of and Amendments to the Claims

Claims 1-57 are canceled herein, without prejudice to renewal or filing in one or more continuation and/or divisional applications. Claims 1-44 are canceled as drawn to non-elected invention groups. Claims 45-57, drawn to the elected invention group, are canceled and re-drafted as new claims 58-72.

New claims 58-72 find support throughout the application and add no new matter. Support for new claim 58 and claims which depend from it includes, but is not limited to, original claim 45; page 5 line 26 - page 6 line 3; page 6 lines 7-12; page 6 lines 17-20; page 7 line 3 - page 8 line 2; page 9 lines 1-4; page 33 lines 27-31; page 36 line 28 - page 37 line 12; and page 44 line 12 - page 52 line 10. Additional support for claims 61 and 63 is found, for example, at least on page 35 lines 3-12. Additional support for claim 62 is found, for example, at least on page 57 line 28 - page 58 line 14. Additional support for claim 64 is found, for example, at least on page 37 lines 9-12 and page 50 line 1 - page 52 line 10. Additional support for claim 65 is found, for example, at least on page 38 line 29 - page 44 line 11. Support for new claim 66 and claims which depend from it includes, but is not limited to, original claim 52;

Application No.: 09/896,896  
Attorney Docket No: 0217us210  
Page 18 of 19  
-----

and page 52 line 21- page 54 line 17. Additional support for claim 68 is found, for example, at least on page 55 line 21 – page 57 line 27; and page 58 lines 15-20.

#### Restriction

The claims were restricted under 35 U.S.C. § 121 into the following groups:

- I. Claims 1, 3, and 5-36, drawn to a glycosylated polypeptide, classified in class 530, subclass 300, and class 514, subclass 8.
- II. Claims 2 and 4, drawn to a glycosylated polypeptide, classified in class 530, subclass 300, and class 514, subclass 8.
- III. Claims 37-44, drawn to glycosylated polynucleotide (*Applicants respectfully wish to clarify that the polynucleotide is not glycosylated*), vector and cell line for the polynucleotide directed biosynthesis of the polypeptide, classified in class 536, subclass 23.1, class 435, subclass 320.1 and 69.1.
- IV. Claims 45-57, drawn to a method of preparing a glycosylated polypeptide by preparing a nucleotide sequence (via mutagenesis), classified in class 435, subclass 440, 69.1 and 320.1, and class 635, subclass 23.1.

#### Election

Applicants elect Group IV, without traverse, for prosecution in this application. New claims 58-72 are drawn to invention Group IV.

Application No.: 09/896,896  
Attorney Docket No: 0217us210  
Page 19 of 19  
-----

### CONCLUSION


This amendment cancels 57 claims and adds 15 claims. If a fee beyond that already authorized for the extension of time is required for entry of this Amendment, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0990.

If a telephone conference would expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (650) 298-5452.

Maxygen, Inc.  
Intellectual Property Dept.  
515 Galveston Drive  
Redwood City, CA 94063  
Customer Number 30560

Phone: (650) 298-5452 (direct)  
(650) 298-5300 (main)  
Fax: (650) 298-5446

Respectfully submitted,



Joanne R. Petithory, Ph.D.  
Reg. No. 42,995